Studies in Patients With Multiple Myeloma and Renal Failure Due to Myeloma Cast Nephropathy
Status:
Completed
Trial end date:
2017-12-01
Target enrollment:
Participant gender:
Summary
MYRE is a phase III multicentric controlled national clinical trial conducted in patients
with multiple myeloma and renal failure related to myeloma cast nephropathy (MCN). Its aims
are to assess (1) the efficacy of bortezomib plus dexamethasone (BD), compared with
cyclophosphamide, plus bortezomib and dexamethasone (C-BD) in patients with inaugural MCN not
requiring hemodialysis; and (2) in patients with inaugural severe renal failure secondary to
biopsy-proven MCN and requiring hemodialysis that of an intensive hemodialysis regimen using
either a dialyser with very high permeability to proteins (TheraliteTM) or a conventional
high-flux dialyser, while receiving chemotherapy with BD.